Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Reneo Pharmaceuticals (RPHM) Stock Forecast & Price Target

Reneo Pharmaceuticals logo
Get the Latest News and Ratings for RPHM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Reneo Pharmaceuticals and its competitors.

Sign Up

RPHM Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
3 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$2.83$11.01$11.01$32.78
Forecasted Upside55.68% Upside505.08% Upside610.48% Upside442.63% Upside
Consensus Rating
Reduce
Reduce
Reduce
Buy

RPHM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RPHM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Reneo Pharmaceuticals Stock vs. The Competition

TypeReneo PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
1.88
2.80
2.50
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside55.68% Upside26,390.75% Upside8.55% Upside
News Sentiment Rating
Neutral News

See Recent RPHM News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/14/2024HC Wainwright
2 of 5 stars
M. Kapoor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.50-5.66%
12/15/2023Leerink Partners
1 of 5 stars
 Reiterated RatingOutperform ➝ Market Perform
12/15/2023Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuy ➝ Hold
12/14/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
12/14/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform
12/14/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
12/14/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$25.00 ➝ $4.00+247.82%
12/14/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$28.00 ➝ $3.00+160.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:28 PM ET.


RPHM Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Reneo Pharmaceuticals is $2.83, with a high forecast of $4.00 and a low forecast of $1.50.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last twelve months. There is currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" RPHM shares.

According to analysts, Reneo Pharmaceuticals's stock has a predicted upside of 55.68% based on their 12-month stock forecasts.

Analysts like Reneo Pharmaceuticals less than other "medical" companies. The consensus rating for Reneo Pharmaceuticals is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RPHM compares to other companies.


This page (NASDAQ:RPHM) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners